Prosecution Insights
Last updated: November 04, 2026
Application No. 18/914,899

NICOTINAMIDE ADENINE DINUCLEOTIDE (NAD) COMPOSITIONS, METHODS OF MANUFACTURING THEREOF, AND METHODS OF USE THEREOF

Non-Final OA §112§DP
Filed
Oct 14, 2024
Priority
May 04, 2021 — provisional 63/183,714 +2 more
Examiner
SHOMER, ISAAC
Art Unit
1612
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Sovida Solutions Ltd.
OA Round
1 (Non-Final)
63%
Grant Probability
Moderate
1-2
OA Rounds
10m
Est. Remaining
93%
With Interview

Examiner Intelligence

Grants 63% of resolved cases
63%
Career Allowance Rate
757 granted / 1200 resolved
+3.1% vs TC avg
Strong +30% interview lift
Without
With
+30.3%
Interview Lift
resolved cases with interview
Typical timeline
2y 11m
Avg Prosecution
61 currently pending
Career history
1263
Total Applications
across all art units

Statute-Specific Performance

§101
1.0%
-39.0% vs TC avg
§103
45.8%
+5.8% vs TC avg
§102
11.5%
-28.5% vs TC avg
§112
25.9%
-14.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1200 resolved cases

Office Action

§112 §DP
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. Claim Interpretation Claim 54 recites the term “lecithin.” As best understood by the examiner, phosphatidylcholine is a type of lecithin. See e.g. Perricone (US 2014/0079761 A1), abstract. Claim 54 recites the term “liposome.” The examiner has provided the following explanation of how the term “liposome” is defined. As an initial matter, a review of the instant specification would appear to indicate that the specification did not redefine the term “liposome” in a manner that differs from the ordinary definition of the term. As such, the examiner has interpreted the term “liposome” in accordance with its ordinary definition; this definition is explained in further detail below. As best understood by the examiner, the ordinary definition of the term “liposome” would appear to entail the presence of an artificial structure comprising one or multiple lipid bilayers. To further explain this, the examiner cites Robson et al. (Frontiers in Pharmacology, Vol. 9, Article 80, February 2018, pages 1-8). Robson et al. (hereafter referred to as Robson) is drawn to techniques for characterizing liposome morphology, as of Robson, page 1, title and abstract. Robson teaches the following figure showing the structure of a liposome on page 3, which is reproduced below. PNG media_image1.png 782 1102 media_image1.png Greyscale As such, a liposome comprises a lipid bilayer, as shown in the above-reproduced figure. As best understood by the examiner, liposomes comprise an aqueous interior and aqueous continuous phase. Therefore, compositions lacking the required lipid bilayer are not understood to be liposomes. The examiner further clarifies here that emulsions are not liposomes, and that micelles are not liposomes. In support of this position, the examiner cites Balamurugan et al. (The Pharma Innovation Journal, Vol. 7(7), 2018, pages 779-789). Balamurugan et al. (hereafter referred to as Balamurugan) is drawn to lipid drug delivery, as of Balamurugan, page 779, title and abstract. Balamurugan teaches the difference between various drug delivery vehicles as of figure 1, reproduced below from page 780. PNG media_image2.png 684 1456 media_image2.png Greyscale The above-reproduced figure shows that liposomes comprise a lipid bilayer. In contrast, micelles, nanoemulsion droplets, and solid lipid nanoparticles or nanolipidic carriers have a lipid monolayer at their surface rather than a lipid bilayer. Liposomes therefore have an aqueous core, whereas micelles and oil in water emulsions have an oily, hydrophobic, and/or lipidic core. As such, micelles, emulsions, solid lipid nanoparticles, or nanolipidic carriers (as in the above-reproduced figure) are not liposomes. Regarding claim 65, the examiner understands that the phrase “homogeneous” requires that the liposomes be distributed homogeneously in the liquid in which they are suspended. It is not understood to require that all of the individual lipid molecules are distributed homogeneously in the solvent. Claim Rejections - 35 USC § 112(b) – Indefiniteness The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 54-73 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 54 recites that the composition is in the form of a liposome. However, claim 67 recites that the composition is an emulsion. The skilled artisan would have understood a liposome and an emulsion to be completely separate structures. The skilled artisan would have understood that a composition which is an emulsion cannot be a liposomal composition and vice versa. See the section above entitled “Claim Interpretation” in which the interpretation of the term “liposome” is explained in greater detail. As such, it is unclear if the instant claims are drawn to a liposome or an emulsion. For the purposes of examination under prior art, the examiner understands the claims to be drawn to a liposome. The examiner will examine claim 67 with the understanding that the term “emulsion” is not actually recited by the claim. In order to overcome this rejection, applicant may cancel “emulsion” from claim 67. Claims 54-73 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 54 recites that the composition is in the form of a solution. However, as best understood by the examiner, a liposome cannot be in the form of a solution. This is because the term “solution” refers to a material in which the solute is homogeneously mixed in the solvent. However, a liposome in water is in the form of a supramolecular structure and the individual lipid molecules are not homogeneously mixed with the water molecules of the solvent because the lipids form a liposome, which is a supramolecular structure. See the section above entitled “Claim Interpretation” in which the interpretation of the term “liposome” is explained in greater detail. As such, it is unclear if the instant claims are drawn to a liposome or a solution. For the purposes of examination under prior art, the examiner understands the claims to be drawn to a liposome. The examiner will examine claim 67 with the understanding that the term “solution” is not actually recited by the claim. In order to overcome this rejection, applicant may cancel “solution” from claim 67. Claim Rejections - 35 USC § 112(d) – Failure to Limit Parent Claim The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph: Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claim 67 is rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Claim 67 recites that the composition is in the form of a suspension. However, claim 54, upon which claim 67 ultimately depends, recites a composition of liposomes in water. The composition of liposomes in water is already in the form of a suspension because the liposomes are suspended in water. As such, that claim 67 recites a suspension would appear to render claim 67 as not further limiting claim 54 upon which it depends. In order to overcome this rejection, applicant may cancel the term “suspension” from claim 67. Relevant Prior Art – No Rejection The examiner notes the following relevant prior art documents over which the instant claims have not been rejected. Sloat Reference: As relevant prior art, the examiner cites Sloat et al. (US 2021/0251917 A1). Sloat et al. (hereafter referred to as Sloat) is drawn to nanoparticle compositions for delivery of cannabidiol, as of Sloat, title and abstract. Sloat teaches topical delivery in paragraph 0143. As a particularly relevant embodiment, the examiner notes Table 28 of Sloat, which is reproduced below. PNG media_image3.png 330 646 media_image3.png Greyscale PNG media_image4.png 290 646 media_image4.png Greyscale The composition in the above-reproduced table comprises water, phosphatidylcholine (i.e. lecithin), pentylene glycol, Vitamin E (i.e. tocopherol), and glycerol. The composition of Sloat differs from the claimed invention because the composition of Sloat does not contain nicotinamide adenine dinucleotide (NAD+); in contrast, the composition of Sloat comprises a different active agent which is cannabidiol. Nevertheless, even if, purely en arguendo, it would have been prima facie obvious to have substituted nicotinamide adenine dinucleotide (NAD+) in place of cannabidiol, the resultant composition would still not have read on the claimed subject matter. This is because the claimed invention is a liposomal composition, and there is no evidence that the composition of Table 28 of Sloat would have been inherently liposomal. The fact that a certain result or characteristic (e.g. the composition of Sloat being liposomal) may occur or be present in the prior art is not sufficient to establish the inherency of that result or characteristic. See MPEP 2112(IV). In fact, in this case, there are various factors that would appear to go against the idea that the composition of Sloat would have been inherently liposomal. As an initial matter, Sloat appears to teach only 11% water in part D; this may have been insufficient to have formed an aqueous continuous phase. Additionally, Sloat teaches the presence of triglycerides, butter, and squalene, all of which would have favored the formation of a micelle or emulsion rather than a liposome. In support of this position, the examiner cites Morrison (US 2016/0184228 A1), which teaches the following in paragraph 0173, relevant text reproduced below. PNG media_image5.png 154 572 media_image5.png Greyscale The above-reproduced text would appear to indicate that phospholipids would naturally form liposomes, whereas the combination of phospholipids with triglycerides would form emulsion droplets which are filled (i.e. the examiner understands the term “filled” in Morrison to refer to being filled with lipid/oil phase). This would appear to indicate that triglycerides do not naturally form liposomes, and the combination of triglycerides with liposome-forming lipids such as phospholipids would have destroyed the liposomal character of said phospholipid composition. As such, in view of the presence of triglycerides in the above-reproduced composition of Sloat, the skilled artisan would not have expected the composition of Sloat to have been in the form of a liposome. As such, administration of this composition would not have met the claimed requirements even if administered with nicotinamide adenine dinucleotide. McCook Reference: As an additional relevant reference, the examiner cites McCook et al. (US 2008/0233183 A1). McCook is drawn to compositions for topical delivery of bioactive agents, as of McCook, title and abstract. McCook teaches multiple embodiments comprising glycerin and pentylene glycol, for example, as of page 13, Table 15. McCook also teaches a liposome comprising lecithin in paragraph 0008. Nevertheless, McCook differs from the claimed invention for at least the following reasons. First, the amounts of various components in McCook differ from in the claimed invention. For example, in Table 14, McCook teaches 2% of glycerin and 2.25% of pentylene glycol. The amount of glycerin taught by McCook is over an order of magnitude lower than the amount of glycerin required by the instant claims, which recite a minimum of about 30% glycerin. It appears that there would have been no motivation for the skilled artisan to have optimized the amount of glycerin in McCook to have been in the claimed range. Furthermore, there would have been no reasonable expectation that, had the amount of glycerin been increased to be in the instantly claimed range, the resultant composition administered by the method of McCook would have been liposomal (as opposed to micellar or an emulsion). In support of this position, the examiner notes that many of the final compositions of McCook include Carbomer as the predominant ingredient; see e.g. Tables 16-18 on page 14 of McCook. Carbomer is an alternate name for polyacrylic acid or polyacrylate. Polyacrylic acid is a polymer comprising repeating carboxylic acid groups. Polyacrylic acid does not contain lipidic moieties and therefore cannot form liposomes. As such, it is unclear that the composition of McCook would have successfully formed liposomes in the case wherein the predominant ingredient is a polymer not capable of liposome formation. Additionally, McCook does not teach NAD+. In fact, the active agent actually administered by McCook is CoQ10, as of McCook, abstract. CoQ10 would appear to be hydrophobic, as of McCook, abstract – McCook uses the term “lipophilic” but the examiner understands this to have essentially the same meaning as “hydrophobic.” In contrast, NAD+, as required by the instant claims, would appear to be hydrophilic because it is soluble in water. There would have been no motivation for the skilled artisan to have substituted a hydrophilic drug such as NAD+ in place of the lipophilic/hydrophobic drug of McCook because McCook specifically indicates that its formulation is for lipophilic drugs. Additionally, there would have been no expectation that a method of delivery of a hydrophobic drug, as in McCook, would have successfully delivered a hydrophilic drug, as delivery strategies differ between hydrophilic and hydrophobic drugs. Khan and Obeidat References: As relevant prior art, the examiner cites Khan et al. (American Journal of Physiology Lung Cell and Molecular Physiology, Vol. 282, 2002, pages L1082-L1091). Khan et al. (hereafter referred to as Khan) is drawn to liposomal NAD+, as of Khan, page L1082, title and abstract. Khan teaches the following in regard to preparation of the liposome, as of Khan, page L1084, right column, relevant text reproduced below. PNG media_image6.png 620 626 media_image6.png Greyscale The above-reproduced text describes a liposome made from NAD+ and egg phosphatidylcholine, which is lecithin, as well as water. The liposome of Khan is being investigated for its potential to have therapeutic effect when delivered to the lungs; this is evident in view of the fact that (a) Khan is treating hypoxia and (b) the journal in which the Khan article is published is taught to relate to lung physiology. Khan differs from the claimed invention because Khan does not teach glycerin, pentylene glycol, and tocopherol, let alone in the required amounts. The examiner conducted a search regarding the ingredients required by the claims and missing from Khan, and from that search, the examiner takes the position that the skilled artisan would not have been motivated to have modified Khan by adding pentylene glycol in the required amount. This is because a search conducted by the examiner indicated that pentylene glycol is used as a skin moisturizer. See Obeidat et al. (European Journal of Pharmaceutics and Biopharmaceutics, Vol. 76 (2010), pages 56-67). Obeidat et al. (hereafter referred to as Obeidat) is drawn to nanostructured lipid carriers, as of Obeidat, page 56, title and abstract. Obeidat teaches the following regarding pentylene glycol, as of page 57, left column, relevant text reproduced below. PNG media_image7.png 120 586 media_image7.png Greyscale As such, the skilled artisan may have been motivated to have added pentylene glycol to a topical composition intended for administration to the skin. However, the composition of Khan is not actually intended for topical administration to the skin; in contrast, the composition of Khan is intended for administration to the lung. As such, the skilled artisan would not have been motivated to have combined pentylene glycol with the composition of Khan. A statement that modifications of the prior art to meet the claimed invention would have been "‘well within the ordinary skill of the art at the time the claimed invention was made’" because the references relied upon teach that all aspects of the claimed invention were individually known in the art is not sufficient to establish a prima facie case of obviousness without some objective reason to combine the teachings of the references. See MPEP 2143.01(IV). In this case, there does not appear to be an objective reason to combine the pentylene glycol of Obeidat with the liposome of Khan because Obeidat teaches pentylene glycol for topical uses on the skin, which is not the intended use of the liposome of Khan. Non-Statutory Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 54-66 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-5 of U.S. Patent No. 12,150,461. Although the claims at issue are not identical, they are not patentably distinct from each other because of the following reasons: The instant claims are drawn to a liposome composition. This composition comprises NAD+, lecithin, water, glycerol, pentylene glycol, and tocopherol in specific proportions. The conflicting claims are drawn to a method of topically administering a liposome composition having the following components. PNG media_image8.png 276 486 media_image8.png Greyscale The instant and conflicting claims differ because the instant claims are drawn to a composition, whereas the conflicting claims are drawn to a method of topically administering a particular composition. Nevertheless, the composition administered in the method of the conflicting claims is liposomal and has the same components as the instantly claimed composition. As such, the conflicting claims appear to recite all of the limitations required by the instant claims. Therefore, the conflicting claims appear to effectively anticipate the instant claims, resulting in a prima facie case of anticipatory-type non-statutory double patenting in regard to instant claims 54-55. As to instant claims 56-64, the composition used in the method of the conflicting claims appears to have the required stability, as of conflicting claims 3-5. As to instant claim 65, the composition used in the method of the conflicting claims would appear to have the liposomes suspended homogeneously in an aqueous environment. This is because the composition recited by the conflicting claims is described as stable in the conflicting claims. The skilled artisan would have expected inhomogeneity to have been grounds for instability because inhomogeneity would have resulted in multiple liposomes aggregating together, thereby resulting in an inhomogeneous composition. As the composition of the conflicting claims is described as stable, it is understood to therefore be homogeneous. As to instant claim 66, the skilled artisan would have expected that the composition of the conflicting claims would have been liquid because it is primarily made from water and glycerol, which are both liquids. Claims 67-73 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-5 of U.S. Patent No. 12,150,461 in view of Gupta (US 2006/0110415 A1). The instant claims are drawn to a liposome composition. This composition comprises NAD+, lecithin, water, glycerol, pentylene glycol, and tocopherol in specific proportions. The conflicting claims are drawn to a method of topically administering a liposome composition having the same components as the instantly claimed composition. The conflicting claims do not recite a drug delivery form such as a serum, cream, ointment, gel, lotion, or foam. Gupta is drawn to a composition intended for topical administration, as of Gupta, title and abstract. Gupta teaches a form of lotions, creams, gels, and foams in paragraph 0047. Gupta teaches an ointment in paragraph 0096 and a serum in paragraph 0048. Gupta differs from the claimed invention at least because Gupta does not teach NAD+ as the active agent. It would have been prima facie obvious for one of ordinary skill in the art to have formulated the composition used in the method of the conflicting claims into the types of composition taught by Gupta. The conflicting claims are drawn to a method of topical administration of a particular composition. As such, the skilled artisan would have been motivated to have formulated the composition administered topically in the method of the conflicting claims into various forms known for topical administration. As the lotions, creams, gels, serums, ointments, and foams of Gupta are known formulations for topical administration, the skilled artisan would have been motivated to have formulated the composition of the conflicting claims into these drug delivery forms in order to have predictably achieved topical administration with a reasonable expectation of success. Conclusion No claim is allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to ISAAC SHOMER whose telephone number is (571)270-7671. The examiner can normally be reached 7:30 AM to 5:00 PM Monday Through Friday. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Sahana Kaup can be reached at (571)272-6897. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. ISAAC . SHOMER Primary Examiner Art Unit 1612 /ISAAC SHOMER/ Primary Examiner, Art Unit 1612
Read full office action

Prosecution Timeline

Oct 14, 2024
Application Filed
Aug 04, 2026
Non-Final Rejection mailed — §112, §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778875
COSMETIC COMPOSITION COMPRISING A CATIONIC ASSOCIATIVE POLYMER, A CARBOXYLIC ANIONIC SURFACTANT, OPTIONALLY A NONIONIC SURFACTANT AND AN AMPHOTERIC OR ZWITTERIONIC SURFACTANT
4y 4m to grant Granted Nov 03, 2026
Patent 12779011
CYCLOSPORINE FORMULATIONS FOR USE IN THE PREVENTION OR TREATMENT OF PULMONARY CHRONIC GRAFT REJECTION
3y 3m to grant Granted Nov 03, 2026
Patent 12766100
In Vivo Targeting of Extracellular Vesicles
3y 11m to grant Granted Oct 20, 2026
Patent 12766109
SUGAR-COATED MELANIN NANOPARTICLES AND METHOD FOR TARGETING METASTATIC CANCER CELLS
3y 7m to grant Granted Oct 20, 2026
Patent 12766203
METHOD FOR PRODUCING RADIOACTIVE ZIRCONIUM COMPLEX
3y 6m to grant Granted Oct 20, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
63%
Grant Probability
93%
With Interview (+30.3%)
2y 11m (~10m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1200 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month